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Arterial medial calcification is a major complication in
patients with chronic kidney disease and is a strong predictor
of cardiovascular and all-cause mortality. We sought to
determine the role of dietary phosphorus and the severity of
uremia on vascular calcification in calcification-prone DBA/2
mice. Severe and moderate uremia was induced by renal
ablation of varying magnitudes. Extensive arterial-medial
calcification developed only when the uremic mice were
placed on a high-phosphate diet. Arterial calcification in the
severely uremic mice fed a high-phosphate diet was
significantly associated with hyperphosphatemia. Moderately
uremic mice on this diet were not hyperphosphatemic but
had a significant rise in their serum levels of fibroblast
growth factor 23 (FGF-23) and osteopontin that significantly
correlated with arterial medial calcification. Although there
was widespread arterial medial calcification, there was no
histological evidence of atherosclerosis. At early stages of
calcification, the osteochondrogenic markers Runx2 and
osteopontin were upregulated, but the smooth muscle cell
marker SM22a decreased in medial cells, as did the number
of smooth muscle cells in extensively calcified regions. These
findings suggest that phosphate loading and the severity of
uremia play critical roles in controlling arterial medial
calcification in mice. Further, FGF-23 and osteopontin may be
markers and/or inducers of this process.
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Chronic kidney disease (CKD) is a worldwide public health
problem with high cost, poor outcome, and increasing
prevalence. Cardiovascular disease is the leading cause of
death among end-stage renal disease (ESRD) patients1 and
their risk of cardiovascular mortality is 10–100 times greater
than in healthy individuals.2 Vascular calcification, the
pathological deposition of calcium phosphate salts in
cardiovascular tissues, is highly correlated with cardiovas-
cular mortality in both pediatric and adult CKD patients.3–5
Vascular calcification can occur in the arterial intimal layer in
association with atherosclerosis, or in the arterial medial layer
independent of atherosclerotic disease.
Arterial medial calcification (AMC), is a hallmark of CKD
and has emerged as a strong prognostic marker for all-cause
mortality in dialysis patients.4,6 At the artery level, AMC
results in increased wall stiffness, decreased compliance, and
increased pulse-wave velocity and systolic pressure. Over
time, these altered mechanical and hemodynamic properties
lead to left ventricular hypertrophy, decreased coronary
perfusion, and heart failure.3,4 At the arteriole level, AMC
causes the ischemic skin lesions characteristic of calcific
uremic arteriolopathy (CUA), a condition almost exclusively
observed in dialysis patients and associated with an extremely
high mortality rate.7,8
The mechanisms regulating vascular calcification are still
under investigation. However, it is currently accepted that the
process is complex, involving the active participation of a
number of calcification inducers and inhibitors.9 The
interaction between the regulators, as well as their roles in
the initiation and/or progression of the calcification process,
is still unknown. Phosphate has emerged as a major promoter
of vascular calcification and is increasingly adopting a central
role in the calcification process. Hyperphosphatemia is a
persistent, prevalent problem in ESRD patients, and epide-
miological studies have revealed that elevated serum
phosphorus is a strong predictor of morbidity and cardio-
vascular mortality in dialysis patients.10,11 Also, growing
evidence indicates that hyperphosphatemia is correlated with
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calcification of the coronaries, peripheral arteries, and cardiac
valves as well as with CUA in ESRD patients.12–14 Effective
control of hyperphosphatemia without increasing total
calcium load has been correlated with attenuated progression
of vascular calcification in prevalent dialysis patients,15,16 and
decreased mortality in incident dialysis patients.17 Moreover,
even relatively small elevations in serum phosphate in the
high normal range (3.5–4.5 mg/dl) have been correlated with
increased risk of cardiovascular and all-cause mortality in
both CKD patients11 and non-uremic patients with coronary
disease.18 Thus, it is important to determine whether
phosphate load, even in the absence of outright hyperpho-
sphatemia, is an important driver of vascular calcification.
To date, mechanistic and genetic studies of uremia-
induced AMC have been hampered by lack of a robust mouse
model in which AMC occurs in the absence of atherosclerotic
disease, but nevertheless mimics the extensive AMC observed
in patients with ESRD.19 In this study, we describe a uremic
mouse model of extensive, widespread AMC that was not
associated with atherosclerotic disease, and was dependent on
the degree of renal insufficiency and phosphate feeding. AMC
was associated with early osteochondrogenic phenotype
change and late medial cell loss, and correlated with serum
FGF-23 and OPN levels.
RESULTS
AMC and serum biochemistry in severely uremic, high
phosphate-fed mice
To determine the effect of renal insufficiency and phosphate
loading on AMC, severe uremia was induced in mice using a
two-step severe renal ablation surgery, and mice were fed a
normal or high phosphate diet as described in the Materials
and methods section. Figure 1 shows the aortic calcium
content in the severely uremic groups and their sham
controls at termination. High levels of aortic calcium were
detected in the severe uremia/high phosphate (SU/HP) group
(18.2±7.3 mg/mg dry wt). In contrast, very little aortic
calcium was detected in the severe uremia/normal phosphate
(SU/NP) group (1.1±0.3 mg/mg dry wt) and this was not
significantly different from sham controls (1.0±0.2 mg/mg
for the Sham/NP and 1.0±0.3 mg/mg for the Sham/HP).
These data suggest that uremia alone, in the absence of a
dietary phosphate load, was not sufficient to induce AMC in
these mice.
Mineralization of the arteries was visualized in whole
mounts and cross sections by alizarin red staining for
calcium. Mineral deposits in the SU/HP mice were extensive
and widespread and included all portions of the arterial tree
(Figure 2a). The aortic arch, upper and lower thoracic aorta,
and abdominal aorta were consistently affected. The mid-
portion of the thoracic aorta was a site that was consistently
spared of calcification. In addition, smaller arteries, such as
the iliac, renal, and mesenteric vessels and their derivatives,
appeared to be more severely calcified compared with the
large, central arteries, suggesting that these smaller diameter
peripheral arteries may be highly susceptible to calcification
(Figure 2a, and data not shown). Representative alizarin
red–stained cross sections for the abdominal aorta, carotid,
iliac, and mesenteric arteries are shown in Figure 2b–e. In
these vessels, calcification was most often circumferential and
was restricted to the tunica media with no evidence of
endothelial or adventitial involvement (Figure 2f and g). In
agreement with aortic calcium quantitation (Figure 1), no
calcification was histologically detectable in the Sham/NP,
Sham/HP, or SU/NP groups (Figure 2j–m). In addition to
vessels, we observed that some other soft tissues were also
calcified in this model, including myocardium and lungs
(data not shown).
As shown in Table 1, mice with severe uremia had blood
urea nitrogen (BUN) values about threefold higher than non-
uremic, sham controls (70±4 and 62±4 mg/dl for SU/NP
and SU/HP, respectively versus 22±1 and 21±1 mg/dl for
Sham/NP and Sham/HP, respectively). However, as shown in
Figure 3a, only the mice in the SU/HP group developed
significant hyperphosphatemia. As shown in Figure 3b,
although a statistically significant increase in serum calcium
levels was observed in the SU/NP group compared with all
other groups, these mice did not develop aortic calcification
(Figure 1) and linear regression analysis revealed no
correlation between serum calcium levels and aortic calcifica-
tion (R¼ 0.28). Calcium X phosphorus products (Ca X P) in
each group (Figure 3c) mirrored the trends observed with
serum phosphorus (Figure 3a) revealing a significant increase
in the product only in the SU/HP group. Furthermore, linear
regression analysis revealed only a weak correlation between
serum phosphorus levels and aortic calcification in SU mice
(R¼ 0.61; Po0.05) as shown in Figure 3d.
A statistically significant increase in serum parathyroid
hormone (PTH) levels was present in SU/NP and SU/HP
mice compared with sham controls (Table 1). Consistent
with previous studies in uremic mice fed a normal phosphate
diet,20 serum alkaline phosphatase (ALP) levels were elevated
in the SU/NP as well as in SU/HP groups compared with
sham controls (Table 1). These data suggest increased bone
remodeling in the uremic mice, and indeed, in other studies
we have observed increased cortical porosity and increased %
trabecular bone volume (BV/TV) in uremic, high phosphate-
fed mice compared with sham controls (data not shown).
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Figure 1 | Aortic calcium content in severely uremic mice and
sham controls under normal and high-phosphate feeding
conditions. Dotted lines indicate mean values for each group.
(Po0.05, analysis of variance); Sham/NP, n¼ 5; Sham/HP, n¼ 6;
SU/NP, n¼ 4; SU/HP, n¼ 7. HP, high phosphate; NP, normal
phosphate; SU, severe uremia.
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However, no arterial calcification was observed in the SU/NP
group despite elevated PTH and ALP.
AMC and serum biochemistry in moderately uremic, high
phosphate-fed mice
To investigate the effects of the degree of renal insufficiency
on AMC, mice were made moderately uremic by less severe
renal ablation, and fed a high phosphate diet as described in
the Materials and methods section. Figure 4 shows the aortic
calcium content in the moderately uremic groups and sham
controls at termination. A significant increase in aortic
calcium content was detected in the MU/HP group
(5.9±2.7 mg/mg dry wt) compared with the MU/NP
group (0.7±0.09 mg/mg dry wt) and the sham controls
(0.7±0.1 mg/mg for the Sham/NP and 0.9±0.1 mg/mg
for the Sham/HP). Furthermore, a threefold decrease in
L L
L
L
Figure 2 | Histological analyses of AMC in uremic mouse arteries. (a) Alizarin red staining of vascular tree whole mount. B–M,
Representative micrographs of alizarin red–stained paraffin sections of arteries in the different study groups; (b) abdominal aorta; (c) carotid;
(d) iliac; and (e), mesenteric artery in uremic, high phosphate–fed mice (scale bar¼ 100 mm for (b–d), and 50 mm for (e)). Extensive
mineralization exclusively in the tunica media was observed in the SU/HP group (f, aortic arch and g, aortic arch; scale bar¼ 30mm, aortic
arch). Early mineralization foci were often observed in the elastic lamella (h, aortic arch) and in the extracellular matrix between lamellae
(i, aortic arch) in the MU/HP group (scale bar¼ 30mm). No arterial calcification was observed in the aorta of mice from the Sham/NP group (j), Sham/
HP group (k), SU/NP group (l), or MU/NP group (m) (scale bar¼ 25mm). L¼ lumen. HP, high phosphate; Mu, moderate uremia; NP, normal
phosphate; SU, severe uremia.
Table 1 | Serum biochemical data and body weights in the severely uremic study
Study groups n Body weight (g) BUN (mg/dl) PTH (pg/ml)* ALP (U/L) Cholesterol (mg/dl)
Sh/NP 5 26.2±0.7a,b 22±1e,f 60±8i 58±7k,l 104±8o,p
Sh/HP 6 27.8±1.0c,d 21±1 g,h 81±15 j 50±13 m,n 115±4q,r
SU/NP 6 23.1±0.5a,c 70±4e,g 284±47i,j 147±38k,m 177±8o,q
SU/NP 13 22.6±0.5b,d 62±4f,h 463±83 175±20 l,n 162±6p,r
ALP, alkaline phosphatase; HP, 0.9% high-phosphate diet; NP, 0.5% normal-phosphate diet; PTH, parathyroid hormone; Sh, Sham; SU, severely uremic. All data are
means±s.e.m. Values with the same superscript (a–r) are statistically significant by Fisher’s LSD, Po0.05. *PTH: SU/HP group, n=2 (due to limited serum availability).
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aortic calcification was observed in the MU/HP group
(5.9±2.7-mg/mg dry wt; Figure 4) compared with the SU/
HP group (18.2±7.2 mg/mg dry wt; Figure 1) even though
the MU/HP group were treated with the HP diet for at least 9
weeks longer than the SU/HP mice.
Histologically, AMC was also widespread in the MU/HP
mice, but notably less severe than in the SU/HP mice. As
shown for the aorta, foci of mineralization were randomly
scattered along the medial layer, associated with either the
elastic lamellae (Figure 2k) or the extracellular matrix
between lamellae (Figure 2l). Of interest, fragmentation of
the elastic lamella was noted in several sections (data not
shown). Again, no mineralization was observed in the
adventitia or endothelial layers.
As shown in Table 2, mice in the MU/NP and MU/HP
groups had BUN values of 44±1 and 45±2 mg/dl respec-
tively, whereas sham controls had BUN values of 30±2 and
22±1 mg/dl for Sham/NP and Sham/HP, respectively. In
contrast with findings in severely uremic mice, Figure 5a
showed that there was no increase in serum phosphorus
levels in the MU/HP mice (8.3±0.4 mg/dl) compared with
the sham controls (7.7±0.5 and 7.9±0.4 mg/dl for Sham/NP
and Sham/HP). This was despite the presence of a significant
increase in AMC in the MU/HP mice compared with the
other groups (Figure 4), indicating that AMC could occur in
the absence of hyperphosphatemia in moderately uremic
mice. Interestingly, we observed a significant decrease in
serum phosphorus levels concurrent with a significant rise in
serum calcium levels and a significant drop in serum PTH
levels (Figure 5a and b and Table 2) in the MU/NP group
compared with sham controls. These observations are
consistent with the possibility that the rise in serum calcium
levels triggered a feedback downregulation of PTH followed
by a decrease in phosphorus (and calcium) uptake in the
intestines. Noteworthy is that linear regression analysis
revealed no correlation between either serum PTH
(R¼ 0.06),or calcium (R¼ 0.06) and aortic calcification in
the moderately uremic mice. As shown in Figure 5c, Ca X P
levels were not significantly elevated in MU/HP compared
with sham controls, but were decreased in the MU/NP group
mirroring the calcium results (Figure 5b). Interestingly, as
observed for severely uremic mice, there was little correlation
between aortic calcium content and serum phosphate levels
(R¼ 0.464), Po0.05 (Figure 5d) in the MU (HP/NP) mice.
In an attempt to understand the mechanism for the lack of
hyperphosphatemia in the MU/HP group, despite the
presence of the dietary phosphate load and the clear
induction of AMC, we analyzed serum FGF-23 levels in
these mice. FGF-23 has been identified recently as an
important regulator of phosphate homeostasis. As shown in
Figure 6a, phosphate feeding alone was not sufficient to
induce fasting serum FGF-23 in sham controls. On the other
hand, a dramatic, statistically significant increase in fasting
serum FGF-23 levels was observed in the MU/HP mice
compared with all other groups (Figure 6a). Furthermore, as
shown in Figure 6b, linear regression analysis revealed a very
strong correlation between serum FGF-23 levels and aortic
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Figure 3 | Serum phosphorus, calcium, and calciumphosphorus in severely uremic mice. Serum phosphorus (a), calcium (b), and
calciumphosphorus (c) linear regression between serum phosphorus and aortic calcium (d) in severely uremic mice and sham controls
under normal and high phosphate-feeding conditions. Data represent the mean±s.e.m. Statistically significant differences (Po0.05) were
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Figure 4 | Aortic calcium content in moderately uremic mice
and sham controls under normal and high phosphate–feeding
conditions. Dotted lines indicate mean values for each group.
(Po0.05, analysis of variance); Sham/NP, n¼ 7; Sham/HP, n¼ 7;
MU/NP, n¼ 10; MU/HP, n¼ 10.
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calcification (R¼ 0.901; Po0.0001) in MU (HP/NP) and
Sham (HP/NP) groups. Interestingly, when aortic calcium
content of only uremic groups (MU: HP/NP) were correlated
with serum FGF-23, the R value (0.905) still remained
significant (Po0.05).
To determine whether elevated FGF-23 levels led to
increased excretion of phosphate in MU/HP mice and could
thus help explain normal serum phosphorus in these mice
despite a phosphate feeding, we performed the following
experiment. Fasting serum and spot urines were collected
from sham mice fed either a high or low phosphate (normal
serum phosphate and FGF-23 conditions) and moderately
uremic (MU) mice fed the high phosphate for 12 weeks
(MU/HP; BUN¼ 59.0±2.5 mg/dl; serum phosphate
¼ 10.9±0.6 mg/dl; serum FGF-23¼ 820±125 pg/ml). We
then used serum phosphate and creatinine levels and urine
phosphate and creatinine levels to calculate the fractional
excretion of phosphate (FEP) in these mice. We found that
FEP was somewhat lower in sham mice that were fed the
normal phosphate diet vs the high phosphate diet, but this
was not statistically significant. (0.06±0.01 vs 0.26±0.13;
P¼ 0.3). On the other hand, FEP was significantly higher in
MU/HP mice compared with either the sham mice that were
fed a normal phosphate diet (0.55±0.04 vs 0.06±0.01;
P¼ 0.0002), or to the sham mice that were fed a high
phosphate diet (0.55±0.04 vs 0.26±0.13; P¼ 0.06). These
data are consistent with the elevated FGF-23 levels
in MU/HP mice leading to increased fractional excretion
of phosphate in the uremic mice, thus accounting for
maintenance of serum phosphate levels despite high phosphate
feeding. Similar observations in non-uremic transgenic mice
chronically overexpressing FGF-23 have been observed.21
Finally, we examined levels of the circulating calcification
inhibitor, OPN, to determine whether it might play a
role in AMC in this mouse model. As shown in Figure 6c,
a striking statistically significant increase in serum OPN
levels was observed in the MU/HP group compared with
MU/NP, Sham/HP and Sham/NP groups. Furthermore, as
shown in Figure 6d, regression analysis revealed a strong
positive correlation between serum OPN levels and aortic
calcification (R¼ 0.925; Po0.0001) in MU and sham groups.
As in the case of FGF-23, this correlation did not change
significantly (R¼ 0.923, Po0.05) even when shams were
excluded from the correlation calculations suggesting that the
correlation between FGF-23 and aortic calcium content was
independent of the uremic state of the mice. Interestingly, for
the first time, a positive correlation was also observed
between serum FGF-23 and OPN levels (R¼ 0.95;
Po0.0001) as shown in Figure 6e. This likely reflects the
observation that FGF-23 and OPN are both phosphate-
sensitive genes that are likely to be co-regulated by phosphate
loading.22,23
Table 2 | Serum biochemical data and body weights in the moderate uremia study
Study groups n Body weight (g) BUN (mg/dl) PTH (pg/ml)* ALP (U/L)** Cholesterol (mg/dl)
Sh/NP 7 23.7±0.4 30±2d,e,h 142±41 35±11j 109±2k,l
Sh/HP 7 25±1a 22±1f,g,h 144±33 75±13 103±4 m,n
MU/NP 10 23.8±0.4b 44±1d,f 83±10i 91±29 144±4k,m
MU/HP 10 22±0.7a,b 45±2e,g 248±72i 119±14j 153±6 l,n
ALP, alkaline phosphatase; HP, 0.9% high phosphate diet; MU, moderately uremic; NP, 0.5% normal phosphate diet; PTH, parathyroid hormone; Sh, Sham. All data are
means±s.e.m. Values with the same superscript (a–n) are statistically significant by Fisher’s LSD, Po 0.05. *n value for PTH: MU/NP group, n=7; **n value for ALP: Sh/NP group,
n=6; MU/NP group, n=8.
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Immunohistochemistry of calcified arteries
To gain insights into the etiology of AMC in uremic high
phosphate-fed mice, we analyzed arteries for immunochemical
evidence of two potential mechanisms of vascular calcifica-
tion: osteochondrogenic phenotype change and inflamma-
tion. Osteochondrogenic phenotype change was assessed by
examining the expression of smooth muscle and osteochon-
drogenic lineage markers. Figure 7a shows a representative
focus of early mineralization along the elastic lamella in the
aorta of a uremic high phosphate-fed mouse, as indicated
by alizarin red staining (Figure 7a, arrow). Upregulation
of the osteochondrogenic marker, OPN, was detected
both in association with the mineralized elastic lamina
(Figure 7b, arrowhead), as well as in medial smooth muscle
cells (Figure 7b, arrows). In addition, downregulation of the
smooth muscle cell lineage marker, SM22a, was observed in
the cells surrounding the calcified area (Figure 7c). The loss
of SM22a expression was not due to cellular deficiency, as
counterstaining with methyl green (Figure 7c) and adjacent
hematoxylin and eosin (H&E)–stained sections (Figure 7d)
demonstrated nuclei in the calcified area. On the other hand,
adjacent aortic sections (Figure 4e–h) from a non-calcified
uremic mouse fed a normal phosphate diet had no alizarin
red–positive staining (Figure 7e), no OPN expression (Figure
7f), strong SM22a expression (Figure 7g), and normal medial
structure as determined by H&E staining (Figure 7h).
Interestingly, strong Runx2/cbfa1 staining was detected in
the nuclei of medial smooth muscle cells in uremic, high
phosphate-fed mice prior to mineralization, consistent with
its possible role as an initiating event in SMC phenotype
change and calcification (Figure 7i). In contrast, no Runx2/
cbfa1 staining was detected in the non-calcified artery in
Figure 7j. No evidence of SMC phenotype change was
observed in any of the SU/NP, MU/NP, Sham/NP, and Sham/
HP mouse arteries analyzed (data not shown). Finally, no
collagen II staining (indicative of chondrogenic differentia-
tion) was detected in any specimens examined (data not
shown).
Although early foci of calcification were associated with an
osteogenic phenotype change, more heavily calcified regions,
presumably representing later stages of the calcification
process, showed evidence of medial cell loss. Figure 8 shows
representative-stained sections of a severely calcified aorta
from an SU/HP mouse. H&E staining demonstrated
extensive, circumferential calcification as indicated by
basophilic staining in the media (Figure 8a and c) and
alizarin red staining (Figure 8b). SM22 staining was absent in
the calcified areas (Figure 8d), but in contrast to early
calcification sites where loss of SM22 staining occurred due
to phenotypic change (Figure 7), loss of SM22 in the highly
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Figure 6 | Serum FGF-23 and osteopontin levels in moderately uremic mice. Serum FGF-23 (a); correlation between serum FGF-23 and
aortic calcium (b); serum osteopontin (OPN) (c); correlation between serum OPN and aortic calcium (d); correlation between serum OPN and
FGF-23 (e) levels in moderately uremic mice and sham controls under normal and high phosphate-feeding conditions. Data represent the
mean±s.e.m. Statistically significant differences (Po0.05) were observed between groups with same alphabetical notations; Sham/NP,
n¼ 7; Sham/HP, n¼ 7; SU/NP, n¼ 6; SU/HP, n¼ 6.
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calcified specimens appeared to be due to a deficit in medial
cells in these regions. This was as evidenced by lack of nuclear
staining in adjacent H&E sections (Figure 8a and c) and
methyl green counterstaining (Figure 8d). Thus, cell loss was
evident late in the calcification process.
To determine whether inflammation contributed to the
calcification process, we investigated the expression of BM8, a
macrophage-specific surface marker, in representative sec-
tions from all mouse groups. We did not observe any
macrophages associated with either calcified or non-calcified
arterial media in any of the groups (data not shown). Only
occasionally, in extensively calcified regions, did we detect a
few BM8-positive cells in the underlying adventitia (data not
shown), suggesting that inflammation is unlikely to be
driving AMC in this uremic mouse model. Furthermore, no
intimal or neointimal accumulation of macrophages or any
other cell was detected in any of the groups, indicating that
atherosclerotic lesion formation was not associated with
calcification in any of the vessels (Figure 8a and c, and data
not shown).
DISCUSSION
In this study, we describe a uremic mouse model of robust
AMC in the absence of atherosclerosis and associated
L
L
LL
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L
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Figure 7 | Histochemical staining of mildly calcified and non-calcified arteries. (a–d) are adjacent sections capturing an early
mineralization focus in the aorta of a uremic, high phosphate–fed mouse. (a) alizarin red–positive foci of elastin calcification (arrowhead);
(b) osteopontin staining (brown) was detected both in SMC surrounding the calcification focus (methyl green counterstained nuclei, arrows)
as well as along the calcified elastic lamina (arrowhead); (c) SM22a staining (brown) was absent or greatly reduced in the SMC (methyl green
counterstained nuclei) near the calcified focus. (d) Hemotoxylin and eosin (H&E)–stained adjacent section indicates intact SMC in the
calcified areas e–h are adjacent aortic sections of an U/NP mouse showing (e), the absence of alizarin red–positive staining; (f) lack of
osteopontin staining (brown); (g) abundant SM22a staining (brown) in the medial SMC; (h), normal cellular and matrix morphology by H&E
staining; (i) and (j), Runx2/cbfa1-positive nuclear staining (brown) in the aorta of an U/HP mouse (i) or Sham/NP mouse (j). Scale bar 30 mm.
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dc
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L
200 µm 30 µm
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Figure 8 | Immunochemical staining of a severely calcified
artery showing evidence of SMC loss. (a) H&E staining (scale
bar¼ 200 mm), boxed area is shown at higher magnification in
(b–d); (b) Alizarin red staining (scale bar¼ 30 mm); (c) H&E staining
(scale bar¼ 30 mm); (d) SM22a immunostaining (brown) with
methyl green nuclear counterstaining (scale bar¼ 30 mm). Note
the absence of both SM22a staining as well as cell nuclei in the
calcified area (dashed rectangle).
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inflammation. Uremic mice that were fed a normal
phosphate diet did not develop AMC, whereas those fed a
high phosphate diet did. Although uremia in the absence of
phosphate feeding did not induce vascular calcification, the
degree of renal insufficiency was an important modulator of
the extent of AMC in phosphate-fed mice. In severely uremic
mice, high phosphate feeding induced hyperphosphatemia.
On the other hand, moderately uremic mice fed a high
phosphate diet developed AMC under normophosphatemic
conditions. In MU mice, FGF-23 and OPN levels but not
serum phosphate levels were highly correlated with AMC.
Finally, we observed an osteogenic SMC phenotypic change
associated with early stages of calcification, and provide
evidence that late stages of calcification were associated with
medial SMC loss.
Under severe uremic conditions, hyperphosphatemia was
detected and a positive correlation between serum phos-
phorus concentrations and AMC was revealed in uremic
mice. Elevated serum phosphorus levels in association with
uremia and ectopic calcification have also been observed in
rats24,25 as well as LDLR null26,27 and apolipoprotein
E-deficient mice.25,27,28 These findings agree with the growing
clinical evidence that serum phosphorus levels above normal
are a risk factor for vascular calcification even at early stages
of CKD.13,14
On the other hand, the MU/HP group did not show
hyperphosphatemia despite having significant AMC. How-
ever, it should be noted that although MU/HP mice did not
have higher serum phosphorus than non-uremic mice, they
did have higher serum phosphorus than the MU/NP mice.
Although we attempted to avoid post-prandial variations in
serum phosphorus levels by fasting the animals, it is possible
that time-averaged serum phosphorus may be elevated in the
MU/HP mice. Nonetheless, our studies are in agreement with
clinical data, as hyperphosphatemia typically manifests itself
only in the later stages of the renal disease whereas the risk
for vascular calcification starts in the early stage.11,29 It is
interesting to note that several recent studies have correlated
even relatively small elevations in serum phosphate in the
high normal range (3.5–4.5 mg/dl) with increased risk of
cardiovascular and all-cause mortality in chronic kidney
disease patients.11,30 Together, these data suggest that
phosphate burden, even in the absence of overt hyperpho-
sphatemia, plays an important role in vascular calcification
that can contribute to cardiovascular and all-cause mortality
in CKD patients.
A likely explanation for normal serum phosphate levels in
the presence of a dietary phosphate burden in the MU/HP
mice was the striking elevation of serum FGF-23 levels
observed in this group compared with the MU/NP, Sh/NP,
and Sh/HP groups. FGF-23 is a hormone produced by
osteocytes that acts to suppress phosphate reabsorption in
the kidney thus causing increased phosphate excretion.31 In
support of this possibility, we found that the fractional
excretion of phosphate (FEP) in the urine was significantly
higher in MU/HP mice compared with Sh/NP or Sh/HP
mice. Thus, our data support the idea that elevated FGF-23
levels in MU/HP lead to increased FEP in the uremic mice,
thus accounting for maintenance of serum phosphate levels
despite high phosphate feeding. Similar observations in non-
uremic transgenic mice chronically overexpressing FGF-23
have been observed.21 In those studies, transgenic mice
expressing high levels of FGF23 (17,600 RU/ml) had higher
FEP compared with wild-type mice with undetectable serum
FGF23 levels (0.72 vs 0.14; Po0.001). As expected, over-
expression of FGF-23 led to hypophosphatemia in these non-
uremic mice that were fed a chow diet due to chronic high
FEP.
Our findings suggest that in early stages of CKD,
mimicked by the moderate uremia conditions in our study,
serum phosphate levels are largely maintained in the normal
range due to successful protection by FGF-23. Interestingly,
we detected a strong correlation between serum FGF-23 levels
and aortic calcification in uremic mice. On one hand, this
finding was unexpected, as FGF-23 deficiency causes
hyperphosphatemia and vascular calcification in both hu-
mans and mice.21,32–34 However, high serum FGF-23 levels
are reported in CKD and hemodialysis patients,21,35,36 a
population typically having extensive cardiovascular calcifi-
cation,5,37 and a recent study has shown FGF-23 levels are
independently associated with mortality in dialysis patients.38
Our studies showing that FGF-23 levels are highly correlated
with AMC might provide biological plausibility for these
important clinical findings.
Our findings also bring up the interesting possibility that
FGF-23 might serve as a marker of vascular calcification,
which would be particularly useful in the earlier stages of the
disease when serum phosphate levels are in the normal range.
Alternatively, FGF-23 may play some as yet undefined role in
promoting AMC. However, we cannot rule out the possibility
that elevated FGF23 levels may simply reflect a reaction to the
phosphate loading that the mice were subjected to in the
uremic state. More work is needed to distinguish between
these possibilities.
Our studies also indicated that the degree of uremia was
an important modulator of the extent of AMC in mice.
Severe uremic conditions that increased levels of serum PTH
(B3–4 fold), ALP (B3 fold), calcium (B10%), and
cholesterol (B50% ), and that were comparable to changes
in PTH and ALP typically observed in patients with stage 4–5
CKD compared with non-uremic controls,39 were not
sufficient to induce AMC in the absence of a dietary
phosphate load in the SU/NP group. On the other hand,
in the presence of the dietary phosphate load, both
moderately and severely uremic mice developed AMC. To
our knowledge, this is the first animal model demonstrating
that the severity of uremia, though not sufficient to initiate
AMC, played a significant role in the acceleration of the
calcification process.
These studies are the first to show that serum OPN levels
are induced by uremia and high phosphate feeding in mice.
OPN is a secreted phosphoprotein that is normally
1304 Kidney International (2009) 75, 1297–1307
o r i g i n a l a r t i c l e MM El-Abbadi et al.: Vascular calcification and uremia
synthesized in bone and kidney,40 but the expression of which
is highly upregulated in calcified tissues, including
the arteries (Moe et al.6 and Giachelli et al.41 and Figure 7).
In vitro, OPN levels were induced by elevated phosphate
levels in both osteoblasts42 and SMC43–45 indicating that
OPN is a phosphate-responsive gene. Furthermore, we
identified a strong positive correlation between serum OPN
and AMC. As OPN has been shown to be a potent inhibitor
of mineralization,46–49 a possible interpretation of this
unexpected finding is that serum OPN was induced as a
protective mechanism that was overwhelmed in uremic, high
phosphate-fed mice. Alternatively, as OPN phosphorylation
has been shown to be required for its anticalcific activity,47,50
it is possible that circulating OPN was inactive due to
underphosphorylation. Consistent with this possibility, ALP
has been shown to dephosphorylate OPN,48 and was elevated
in the serum of uremic mice. Unfortunately, there are
currently no antibodies available that allow us to distinguish
between phosphorylation states of OPN. Lastly, it is
possible that serum OPN might promote AMC through its
proinflammatory properties.40 However, this is considered
unlikely, as inflammation was not associated with AMC in
this model.
Finally, we addressed possible mechanisms involved in
uremic AMC in the mouse. Prior to mineralization, we
observed elevated Runx2 levels in the media of uremic, high
phosphate-fed mice compared with non-uremic mice. At the
earliest sites of calcium deposition, AMC was associated with
increased OPN expression and decreased SM22a expression,
indicating that an SMC phenotypic change occurred
concomitant with AMC. In contrast to other vascular
calcification models where cartilage-like cells have been
observed,51 the SMC phenotype change in the present study
appeared to be predominantly entrained to an osteogenic
rather than an osteochondrogenic lineage as collagen II was
not expressed in any of the calcified arteries. Whether SMC
phenotype is required for AMC is currently unknown. In
addition, we observed a loss of SMC in severely calcified
vessels. This is interesting, because cell death has been
implicated as an inducer of vascular calcification.52,53
Whether cell loss occurred prior to or as a result of
calcification could not be determined from the present study,
and is currently under investigation. Finally, our results
suggest that inflammation was not a major inducer of AMC
in uremic, high phosphate-fed mice. These findings are
consistent with clinical data, because AMC in humans, unlike
atherosclerotic calcifications, are typically not associated with
inflammation.54
In conclusion, these studies suggest important roles for
phosphate loading and degree of renal insufficiency in
mediating AMC in mice. Furthermore, serum FGF-23 and
OPN were highly correlated with AMC even when serum
phosphorus levels were still in the normal range, suggesting
potential roles for these molecules as markers and/or
etiological mediators of AMC. Finally, the development of a
mouse model for robust arterial medial calcification
following renal ablation opens the door for future mechan-
istic studies using knockout mice bred on the DBA/2
calcification susceptible background.
METHODS
Animals and Diets
Female DBA/2 mice were purchased from Taconic (Germantown,
NY, USA) and Charles River laboratories (Wilmington, MA, USA)
and maintained in a specific pathogen-free environment. DBA/2
mice were chosen based on previous studies demonstrating that
these mice are highly susceptible to ectopic calcification, in contrast
to C57BL/6 that are resistant.55 Female mice were used because they
showed higher susceptibility to calcification than male mice (our
unpublished data, and Qiao et al.56). HP and NP diets were
purchased from Dyets Inc. (Bethlehem, PA, USA). The HP diet
contained 0.9% phosphate, 0.6% calcium, and the NP diet
contained 0.5% phosphate and 0.6% calcium. Mice had access to
food and water ad libitum and were maintained in compliance with
the NIH guide for the Care and Use of Laboratory Animals. The
University of Washington Animal Care Committee approved the
study protocol.
Surgical procedure
Uremia was induced in 20 to 21 week-old mice following the two-
step surgical procedure for partial renal ablation described by
Gagnon and Gallimore.57 Briefly, during surgery 1, the right kidney
was exposed, decapsulated, and electrocauterized. By manipulating
the extent of electrocautery, mice with moderate (MU;B50% renal
ablation) or severe (SU; B75% renal ablation) uremia were
obtained. Following a 2-week recovery period, left total nephrect-
omy was performed (surgery 2). Control mice underwent sham
surgeries, where dorsal incisions were made, the kidneys surfaced
then reinserted into the abdominal cavity. Within 72 h of post
surgery 2, mice were put on either the NP or the HP diets. At
termination, the aortas were collected for calcium quantitation and
histological/immunohistochemical analyses. Carotid, iliac, external
iliac, and mesenteric arteries and hearts and lungs were collected for
histological and immunohistochemical analyses.
Study groups
Severe uremia study. (1) Sham/NP: sham operated mice fed
the NP diet, (2) Sham/HP: sham operated mice fed the HP diet. (3)
SU/NP: mice that underwent severe renal ablation and were fed the
NP diet; and (4) SU/HP: mice that underwent severe renal ablation
and were fed the HP diet. Saphenous blood was collected at week 14
from mice that had been fasted for 3 h. Owing to weakness and
significant percent loss of body weight in the severely uremic group,
all four groups were terminated between weeks 14–15.
Moderate uremia study. (1) Sham/NP, sham operated mice
fed with NP diet (2) Sham/HP, sham operated mice fed with HP diet
(3) MU/NP: mice that underwent moderate renal ablation and were
fed the NP diet; and (4) MU/HP: mice that underwent moderate
renal ablation and were fed the HP diet. Saphenous blood was
collected at week 23 from mice that had been fasted for 3 h, followed
by the termination of all four groups at week 24.
Serum chemistry
Serum chemistries were analyzed by standard autoanalyzer labora-
tory methods performed at Phoenix Central Laboratory (Everett,
WA, USA). Serum PTH, FGF-23, and OPN levels were determined
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using mouse intact PTH-ALPCO ELISA (ALPCO; Salem, NH,
USA), full length FGF-23 ELISA (Kainos Inc., Japan), and OPN
DY441 ELISA (R&D Systems, Minneapolis, MN), respectively.
Quantitative biochemical analysis of aortic calcium
Dissected aortic tissues were frozen, lyophilized and decalcified with
0.6 mM HCl at 371C for 24 h. After centrifugation, the calcium
content of the supernatant was determined colorimetrically with the
o-cresolphthalein complexone reagent using the TECO calcium
diagnostic kit (TECO Diagnostics, Anaheim, CA, USA) as described
earlier.46 Aortic calcium content was normalized to the dry weight of
the tissue and expressed as micrograms of calcium per milligram dry
weight.
Fractional excretion of phosphate (FEP)
Fasting serum and spot urines were collected from unmanipulated
sham mice that were fed either a high or low phosphate diet, and
moderately uremic (MU) mice that were fed the HP diet for 12
weeks. Serum creatinine was measured using the Quantichrom
Creatinine assay kit (BioAssay Systems, Hayward, CA, USA). Serum
phosphorus, urine phosphorus, and creatinine were measured by
autoanalyzer as described above. Fractional excretion of phosphate
was calculated using the following equation: FEC¼ serum creatinine
 urine phosphate/urine creatinin serum phosphate.
Histology and immunohistochemistry
Tissues were fixed in methyl Carnoy’s fixative (3:1, methanol/acetic
acid) overnight, then transferred to 70% ethanol and embedded in
paraffin using an automated tissue processor, and 5 mm sections
were prepared. Alizarin red (0.5%, pH 9.0; Sigma-Aldrich, St Louis,
MO) staining was used to detect calcification whereas H&E staining
was performed for basic histological analysis. For immunohisto-
chemical staining, sections were deparaffinized, rehydrated, then
blocked first with 0.3% H2O2, then with avidin and biotin blocking
reagents (Vector Laboratories, Burlingame, CA, USA) and finally
with PBS containing 0.25–0.5% bovine serum albumin and 4%
serum (same species in which the secondary antibody was raised).46
Polyclonal goat anti-mouse OPN antibody (AF808, R&D Systems,
Minneapolis, MN, USA); monoclonal rat anti-human Runx2/cbfa1
antibody (MAB2006, R&D systems); polyclonal goat anti-mouse
smooth muscle SM 22a antibody (Abcam Inc., Cambridge, MA,
USA); and monoclonal rat anti-murine pan macrophage antibody
(BM-8; Accurate Chemical & Scientific Corp., Westbury, NY, USA)
were utilized. After incubation at room temperature for 1 h, the
sections were incubated with biotinylated secondary antibody
(Vector Laboratories) before streptavidin-conjugated peroxidase
staining using 3,30 diaminobenzidine as chromogen. Counter-
staining was performed with 2% methyl green, followed by
dehydration and mounting. Whole mount alizarin red staining of
the full length aorta was performed as described earlier.58
Statistical analysis
Statistical analyses were performed using the SPSS v16.0 (Chicago,
IL, USA). Group means and variances were determined using
ANOVA unless otherwise noted, and values are presented as
means±s.e.m. Post hoc, pairwise comparisons of group means were
performed using the Fisher’s least significant difference test (LSD),
and differences between groups were considered statistically
significant at a P-value of o0.05. The Pearson’s correlation
coefficient (R) and P-values were used to determine associations.
A positive correlation between two variables, shown as R40.5, was
considered statistically significant at a P-value o0.05.
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